A humanized phenotypic screening platform for chronic pain

Censo Biotechnologies and Cellectricon have joined forces to develop a first-in-kind humanized drug discovery platform to target chronic pain. The platform is based on human induced pluripotent stem cell–derived neurons in combination with Cellectricon's Cellaxess ® Elektra screening system. Th...

Full description

Saved in:
Bibliographic Details
Published inNature methods Vol. 14; no. 6; p. 636
Main Authors Tams, Daniel, Karila, Paul, Barnes, Ashley
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.06.2017
Nature Publishing Group
Subjects
631/154/1435/2417
692/1807/1693/2610
Anticonvulsants
application-note
Bioinformatics
Biological Microscopy
Biological Techniques
Biomedical Engineering/Biotechnology
Biotechnology
Chronic pain
Clinical trials
Disease
Drug development
Electric fields
Genes
Human subjects
Laboratories
Life Sciences
Nervous system
Pain
Pluripotency
Proteomics
Quality control
Stem cells
Online AccessGet full text
ISSN1548-7091
1548-7105
1548-7105
DOI10.1038/nmeth.f.401

Cover

More Information
Summary:Censo Biotechnologies and Cellectricon have joined forces to develop a first-in-kind humanized drug discovery platform to target chronic pain. The platform is based on human induced pluripotent stem cell–derived neurons in combination with Cellectricon's Cellaxess ® Elektra screening system. The combination of highly functional screening with a human cell type of relevance for chronic pain has the potential to enable the generation of better drug candidates for this condition and other diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:1548-7091
1548-7105
1548-7105
DOI:10.1038/nmeth.f.401